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Introduction 
The ideal means for prevention of surgical 
skin wound infections include absolute asepsis 
of the surgical environment and/or sterilization of 
the skin. The first can be achieved by adequate 
implementation of standard surgical techinques 
and procedures. The second goal is only a 
theoretical one because it is impossible to 
completely sterilize the skin. This structure is a 
selective environment in which various microor- 
ganisms live and grow. Moreover; 10-20% of the 
resident flora are in the pilosebaceous units and 
remain even after scrubbing and application of 
antiseptics.' It is important to stress that even 
Staphylococcus epidermidis, a common and 
innocent skin saprophyte, can under certain 
circumstances become virulent and cause minor 
or major  infection^.^,^ Moreover; the skin of the 
centrofacial area is prone to be colonized by 
S. aureus due to nasal carriage of this organism. 
The prevention of wound infection is very 
important when the surgical environment is the 
skin of the face. Here, the aesthetic result of any 
procedure is particularly compromised by wound 
infection. Last, in the central area of the face. 
direct closure of skin defects by approximation 
of the margins is often not feasible because of 
relative lack of tissue in this area. Here more 
aggressive techniques such as skln flap and/or 
free skin grafts are often needed. These procedures 
are subject to a higher risk of infection because 
of possible compromises in vascular supply 
and therefore prophylactic systemic antibiotic 
administration is often provided. 
Mupirocin (Bactroban: pseudomonlc acid 
A) is a new topical antibiotic with a unique chemical 
structure unrelated to that of any other group of 
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antibiotics4 This naturally occurring antibiotic is 
produced by the anaerobic metabolism of a 
particular strain of Pseudomonas f luorescen~.~ 
Mupirocin covers a broad spectrum of Gram- 
positive and Gram-negative bacteria and is 
particularly active against staphylococci (including 
methicillin and multiply resistant stra1ns)"nd 
streptococci (minimum inhibitory concentrations. 
0.1 2-0.5 mg/l).' 
The mode of act~on by which this antibiotic 
inhibits bacterial growth is by inhibiting isoleucyl 
transfer-RNA synthetase which results in the 
inhibition of bacterial pr~teins.'.~ Because of its 
unique mode of action, mupirocin shows neither 
cross-reaction with, nor cross-resistance to, any 
other commonly used and clinically important 
antibiotic.'' The opportunity for the emergence of 
strains of Staphylococcus aureus that are less 
sensitive, and are resistant to antibiotics, exists 
in patients who receive longterm or frequent 
courses of antibiotic therapy, particularly patients 
with chronic inflammatory conditions such as 
atopic dermatitis." When applied as orntment, 
systemic absorption of mupirocin is minimal.12 
The small amount that enters the blood is rapidly 
converted to an inactive metabolite. 90% of which 
is excreted in the urine,13 It may represent a 
better choice of prevention of wound infection in 
areas with a high density of sebaceous glands 
Therefore. the aim of this study was to 
analyze the effectiveness of topical mupirocin for 
the prevention of surgical skin wound infections 
in the centro facial area. 
Materials and Methods 
A prospective study was performed on 273 
patients. One hundred fifty-three were men and 1 2 0  
were women. Mean age was 4521  8 years (range, 
20-63 years) .  All pat ients underwent centers, referred to the sameoperating unit, and 
outpatient surgery for cutaneous proliferative assigned to one of the two study groups using the 
lesions arising in the centrofacial area (nose, method of random a!location by random number 
naso-labial folds, prolabiurn, and chin). Lesions tables. Therefore, there was a single central list. 
arising on the lips were not included. The types and These groups were equivalent in number; age and 
the incidence of the lesions are listed in Table 1 .  sex of patients. In group A, there were 135 patients, 
TABLE 1 .  Type of Lesion 
GROUP A GROUP B 
Pathology Patient Number Percent Patient Number Percent 
Nevi 8 1 60 7 9 57.2 
Sebaceous adenomas 15 1 1 . 1  2 3 16.7 
Fibromas 2 5 18.5 2 1 15.3 
Seborrheic keratosis 13 9.7 14 10.1 
Tr~choepitheliomas 1 0.7 1 0.7 
Total 1 35 138 
The following patients were excluded from the 
study: those with infected eczema, infected burns 
or scalds, systemic lupus erythematosus or severe 
skin disease requiring the use of a systemic 
antibiotic; those who had received toplcal or 
systemic antibiotics within the preceding 48 h; 
those receiving steroids; those with an associated 
disease that might interfere with the study (e.g. 
diabetes); those with renal insufficlency: those 
with suspected pregnancy or lactation; and those 
who were hypersensitive to mupirocin or prepara- 
tions containing polyethylene glycols. 
Investigators had to explain to the patient, 
orally and in writing, the nature. duration and 
purpose of the study, and the possible side- 
effects. Patients were informed that they might 
withdraw from the study at any time, without this 
affecting their future status. 
The patients were divided into two groups. 
They were selected from the different participating 
78 men and 57 women. The mean age was 
44213 years (range. 20-61 years). This group 
was given no antibacterial prophylaxis. In group B, 
there were 138 patients, 75 men and 63 women. 
lblean age was 42+13 years (range, 20-63 years). 
In this group, prophylactic applicat~on of an 
ointment containing 2% mupirocin (Bactroban 
ointment) was performed once a day for 7 days 
prior to surgery The patients were instructed to 
apply it on the lesion and 3 cm around it with 
light massage. 
To avoid extraneous variables, the 
operating room, the sterilization techniques, the 
preparation of the patients, the surgical staff, and 
the surgeons were identical for every operation. 
Immediately before the surgery the operative area 
was scrubbed wit 0.25% benzalkonium chloride 
in alcoholic solution (Citrosil) starting f rorn the 
center to peripheral areas. After scrubbing, the 
skin was blotted with sterile gauze and draped 
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with sterile towels. No occlusive adhesive drape 
was employed. All the operative personnel wore 
caps, masks, and sterile disposable gloves and 
gowns. Polyglactin 91 0 (Vicryl; Ethicon) was the 
suture material for the dermis and monofilament 
nylon (Ethilon: Ethicon) for the skin. 
The. size of the lesions excised ranged 
from 4 to 22 mm (mean, 13.328.7 mm). There 
were no significant differences between the two 
groups in mean size of the lesions excised ( 13.12 
9.2 mm for the major diameter in group A; 13.42 
8.5 mm in group 5). 
All lesions treated were limited in thickness 
to the dermis and excision depth was to the 
subcutaneous plane. Direct approximations are 
the types of surgical procedures for closure of 
the various defects. Subcuticular sutures were 
performed in 105 group A patients and in 8 6  
group B patients. 
The dressings were applied by the same 
physician on the days 2-4 and 6 after surgery. 
Further inspection and dressing changes were 
performed subsequently every second day when 
needed. At each dressing change, the wounds 
were cleansed with 0.25O/o benzalkonium chloride 
in alcoholic solution and covered with sterile gauze. 
The evaluation of the wounds was made inde- 
pendently, by the investigator, the investigator 
had to record on the casereport form, demogra 
phic data such as the pateint's age and sex, the 
nature of the infection, the site of infection, the 
presence or absence of systemic complications 
(e.g. lymphadenopathy and pyrexia), and all 
previous and/or concomitant treatments. A swab 
was also taken from each appropriate site for 
bacteriological evaluation; isolated organisms 
were cultured and their sensitivities to mupirocin, 
penicillin G, tetracycline, chloramphenicol and 
10 
fusidic acid were assessed using the disk diffusion 
susceptibility test. 
ADVERSE EVENTS 
Any adverse events observed by the 
investigator or reported spontaneously by the 
patient were recorded on the patient's case report 
form. The date of onset, duration, intensity, course, 
action taken, outcome and relation to the study drug 
were recorded. The relationship of the adverse 
event to the study drug was categorized as. 
unassessable, unrelated, probably unrelated, 
probably related or related. For each adverse event, 
the decision of whether to withdraw the patient 
from the study and initiate appropriate treatment 
or to continue the study medication was made by 
the investigator 
STATISTICAL ANALYSIS 
In every case, infection was confirmed by 
cultures. The data were analyzed statistically by 
the corrected chisquare test, the odds ratio, 
confidence interval, and Student's t-test. 
Results 
A total of 273 patients were enrolied in 
the study comprising 120 women (aged 2 months- 
50 years; mean, 12.7 years) and 153 men (aged 
3 months-64 years;mean. 2 0  years). There was 
no statistically significant difference between 
the.ages of the women and men enrolled in the 
study (Student's t-test, P>0.05). 
The topical administration of the mupirocin 
ointment was moderately well tolerated by all 138 
group B patients. Ninety two patients had mild 
erythema. Mild to moderate itching was noted by 
32 patients. No patient stopped the medication. 
Eight of 273 patients had wound infections 
(2.93%). The mean age of these 8 patients was 
42.7k6.5 years versus 44.155.5 years (P=NS) 
for the 265 noninfected patients. Seven of these 
8 patients were in group A (2.95%) and one in 
group B (0.48%) (PtO.O1 ) (see Table 2). 
TABLE 2. Comparison of rates infection on the 
groups 
Group A Group B Total 
I + 7 1 8 
O/o 2.95 0.48 2.93 
I - 1 2 8  137 265 
Total 135 138 273 
Odds ratio: 6.043: confidence interval (95  %): 
1.32924.470; chi square.. 6.98 1; P<0.0 1 1' = 
infection; I- = no infection. 
A positive culture was obtained from all 
infected patients: a total of 8 bacterial strains 
were isolated from the lesions, predominantly 
staphylococci (87.5%) and streptococci ( 1  2.5%). 
(Table 3). 
TABLE 3 Bacteriological findings of patients with 
skin infections 
1 findings 1 (8)  I 
1 Bacteriological 
1 Staphylococcus aureus ~ 7 I 
No. of patients affected 
I streptococci 1 1 I 
Discussion 
Surgical infections may be caused by 
pathogens reaching the wound from the patient's 
own skin flora.' Since there is no way to completely 
sterilize the skin, some degree of wound contami- 
nation is inevitable. Therefore, it is important to 
lower the amount of bacterial inoculum as much 
as possible.14 Until now, pharmacological prophy- 
laxis of wound infections depended on the use of 
systemic  antibiotic^.',^ Their use for clean surgical 
procedures is controversia~.'~ We have recently 
shown in a large series of patients that antibiotic 
prophylaxis reduces significantly the rate of 
infection in clean surgical  wound^.^ However; when 
the risk of wound infection is slight, the use of 
antibiotics may not be justified for clean wounds 
due to the poss~brlity of emergence of bacter~al 
antibiotic resistance, risk of system~c allergic 
reactions, and monetary cost.15 Therefore, the use of 
an effective manageable antimicrobial topical agent 
may be of value especially when operating 
on the face, where an optimal aesthetic result is 
extremely important. The  deal antiseptic should 
accomplish the following goals: 1 ) removal of as 
many bacteria as possible from the skin surface 
and destruction of pathogens; 2 )  persistent 
antibacterial effect: 3 )  low cost; and 4)  aesthetic 
acceptability.' 
The use of topical antib~otrcs is appropriate 
in superficial skin wound infections since the 
agents are directly active at the infection site. The 
excessive use of topical antibiotics for such 
infections has increased bacterial resistance both 
to current and to new drugs due to the development 
of cross resistance. As a result many topical drugs 
are not effective. Topical antibiotics should, where 
possible, meet the following requirements: the 
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development of bacterial resistance during therapy 
should be slow, they should either have no or 
have only slow patient sensitization potential and it 
should not be necessary to apply antibacterial 
agents that are also used systemically (because 
of the risk of resistance development). Mupirocin 
meets all these requirements. Owing to its unique 
mode of action and the fact that it is designed 
for topical use only, the risk of resistance 
development is minimal compared with that of 
other topical antibiotics. In vitro experiments with 
susceptible strains of Staphylococous aureus 
revealed that in the presence of mupirocin 
spontaneous resistant mutants developed only 
at a frequency of 1 o - ~  to 1 O-g l6 A recent UK 
multicentre survey examined 8220 strains of 
staphylococci (7 1 7 3  strains of Staphylococcus 
aureus and 1 0 8 3  strains of coagulase-negative 
staphylococci) and showed that only 0 . 3 %  of 
the isolates of S.aureus were resistant (minimum 
inhibitory concentration > 4 mg/l)." The potential for 
sensitization and the development of allergy 
to 2% mupirocin ointment is minimal. In studies 
with healthy volunteers, no evidence of phototoxic 
or photoallergic reactions was observerd.17 In 
addition, the safety and toierance were particularly 
good: no adverse events were reported among 
the 48 patients treated with mupirocin. ointment. 
This study highlighted the importance of 
staphylococci and streptococci in bacterial surgical 
skin infections and the emergence of resistance 
to common drugs, although some of the results 
must be interpreted with care because of the 
small number of strains isolated. 
Mupirocin is particularly valuable against 
staphylococci and streptococci owing to its unique 
mode of action, together with its lack of cross- 
resistance to other antibiotics, and its unavailability 
12 
in systemic form. 
In our study, 2% mupirocin was moderately 
well tolerated by all patients and no allerg~c 
contact dermatitis was observed. It has a broad 
spectrum germicidal activity that persists for at 
least 48 hours on human skin and is increased 
by a high lipid e n v i r ~ n m e n t ~ ~ , ' ~ . ~ ~  In our study 
most infections were caused by strains of 
S. aureus, the usual source of wound infection in 
cutaneous surgery, Even though this organism is 
not normally found in pilosebaceous units. 2% 
Mupirocin may reduce the incidence of S, aureus 
as a transient pathogen. This may be due to the 
drug's high solubility and persistence in lipid rich 
areas, or because it also acts as a peeling agent 
allowing the nonselective physical removal of a 
variety of microorganisms. 
In our study, topical mupirocin was an 
efficacious, safe, and inexpensive agent for the 
prevention of surgical wound infection in the 
seborheic. centrofacial area. 
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